title: A new era for hemophilia B treatment.
abstract: In this issue of Blood, Santagostino et al, in their phase 3 study, demonstrate efficacy and safety of recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) which, along with the other 2 extended half-life FIX products, heralds a new era for the treatment of hemophilia B.
authors.affiliation: OREGON HEALTH & SCIENCE UNIVERSITY AND VA PORTLAND HEALTH CARE SYSTEM;
authors.forename: Jason A
authors.initials: JA
authors.lastname: Taylor
authors.affiliation: BLOODWORKS NORTHWEST.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Kruse-Jarres
mesh_terms: D000418:Albumins / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D005164:Factor IX / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D002836:Hemophilia B / Q000097:blood* / Q000517:prevention & control*; D006801:Humans; D008297:Male
chemical_list: D000418:Albumins; D005164:Factor IX